<i>CIS</i>-2,6-DISUBSTITUTED PIPERIDINES FOR THE TREATMENT OF PSYCHOSTIMULANT ABUSE AND WITHDRAWAL, EATING DISORDERS, AND CENTRAL NERVOUS SYSTEM DISEASES AND PATHOLOGIES

Abstract: <i>Cis</i>-2,6-disubstituted piperidine analogs, or lobeline analogs, having general formula (I) are used to treat diseases of the central nervous system, drug abuse and withdrawal therefrom as well as to treating eating disorders.

Description: C/S-2,6-DISUBSTITUTED PIPERIDINES FOR THE TREATMENT OF PSYCHOSTIMULANT ABUSE AND WITHDRAWAL, EATING DISORDERS, AND CENTRAL NERVOUS SYSTEM DISEASES AND PATHOLOGIES This application claims the benefit of Provisional Application No. 60/146,144, filed on July 30, 1999. Field of Invention The present invention relates to lobelme analogs, specifically -2,6-dιsubstιtuted pipeπdmes, and their method of use m the treatment of diseases and pathologies of the central nervous system (CNS), the treatment of drug abuse and withdrawal therefrom as well as to the treatment of eating disorders such as obesity. Background of the Invention Alpha-Lobelme (lobelme), a hpophilic nonpyridmo, alkaloidal constituent of Indian tobacco, is a major alkaloid in a family of structurally -related compounds found m Lobelia inflata. Lobelme has been reported to have many nicotine like effects, including tachycardia and hypertension (Ohn et al., 1995), hyperalgesia (Hamann et al., 1994) and improvement of learning and memory (Decker et al., 1993). Lobelme has high affinity for nicotmic receptors (Lippiello et al., 1986; Broussolle et al., 1989). However, no obvious structural resemblance of lobelme to nicotine is apparent and structure function relationships between S(-)-mcotme and lobelme do not suggest a common pharmacophore (Barlow et al., 1989). Also, differential effects of lobelme and nicotine suggest that these drugs may not be active through a common CNS mechanism, even though lobelme has been considered a mixed nicotmic agonist/antagonist. Lobelme evokes dopamme (DA) release from rat stπatal slices. However, lobelme evoked DA release is neither dependent upon extracellular calcium nor is it sensitive to mecamylamme, a noncompetitive nicotmic receptor antagonist. Thus, lobelme evoked DA release occurs via a different mechanism than does nicotine to evoke DA release (Teng et al., 1997, 1998; Clarke et al., 1996). In this respect, lobelme also inhibits DA uptake into rat stπatal synaptic vesicles via an interaction with the dihydrotetrabenazme (DTBZ) site on vesicular monoamme transporter-2 (VMAT2), thus increasing the cytosohc DA available for reverse transport by the plasma membrane transporter (DAT) (Teng et al., 1997, 1998) Thus, lobelme interacts with nicotmic receptors and blocks nicotme-evoked DA release, but also interacts with DA transporter proteins to modify the concentration of DA in the cytosohc and vesicular storage pools, thereby altering subsequent dopammergic neurotransmission. SUMMARY OF THE INVENTION The present invention is directed to a method of treating an individual who suffers from a disease or pathology of the central nervous system (CNS) or for treating an individual for drug dependence or withdrawal for drug dependence. The method comprises of admmistenng to the individual an effective amount of a cιs-2,6-substιtuted pipeπdmo compound, i.e., a lobelme analog, including pharmaceutically acceptable salts of such compounds thereof. As used herein, an "effective amount" refers to an amount of a drug effective to reduce an individual's desire for a drug of abuse or for food, or for alleviating at least one of the symptoms of the disease or pathological symptom of a CNS pathology. The compound can be administered alone, combined with an excipient, co-administered with a second drug having a similar or synergistic effect. The compound is administered subcutaneously, intramuscularly, intravenously, transdermally, orally, lntranasally, mtrapulmonary or rectally. The use of cιs-2,6-dιsubstιtuted pipeπdmes and derivatives thereof in treating diseases or pathologies of the CNS is implicated. In particular, the treatment of dependencies of such drugs as cocaine, amphetamine, caffeine, nicotine, phencychdme, opiates, barbiturates, benzodiazepmes, canabmoids, hallucinogens, and alcohol is implicated. Also, the treatment of eatmg disorders such as obesity is implicated. In a preferred aspect of the invention, the method of treatment reduces an individual's desire for the drug of abuse or for food by at least one day, but it is also preferred that the treatment method further comprise administering behavior modification counseling to the individual. Although the compound of the present invention is contemplated pπmaπly for the treatment of drug abuse and withdrawal and for eating disorders, other uses are also suggested by the studies discussed herein. Thus, cognitive disorders, bram trauma, memory loss, psychosis, sleep disorders, obsessive compulsive disorders, panic disorders, myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntmgton's disease, attention deficit disorder, hyperkmetic syndrome, chronic nervous exhaustion, narcolepsy, motion sickness and depression, and related conditions are considered to be susceptible to treatment with a compound of the present invention As shown by the results of the studies described herein, lobelme analogs are found to be effective in inhibiting uptake of extracellular DA by cells of the CNS Some of these analogs are also nicotmic receptor antagonists. Either or both mechanisms can thereby work to alter the distribution of the mtracellular DA pools and as a result alter extracellular DA concentration As used herein the term "lobelme" refers to a compound having the general chemical formula 2-[6-(β-hydroxyphenethyl)-l-methyl-2-pιpeπdyl]-acetophenone. The term "lobelme analogs" and equivalents thereof as used herein, refers to chemical deπvatives of lobelme obtained by oxidation or reduction of lobelme, others obtained by esteπfication of lobelme and redox deπvatives, as well as various substitutions at the N-position of the pipendmyl moiety. DETAILED DESCRIPTION OF THE INVENTION The 2,6-dιsubstιtuted pipeπdme lobelme analogs of the present invention include those contemplated by the following formula (I), without regard to chirality: wherein: n is zero or an integer in the range from 1 to 3; X 1 — Y 1 and X 2 — Y 2 are the same or are independently different from one another and represent a saturated carbon-carbon bond, a cr ' s-carbon-carbon double bond, a trans-caτbon- carbon double bond, a carbon-carbon tπple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond; R 1 and R 4 are the same or are independently different from one another and represent hydrogen or a lower straight chain or branched alkyl or R 1 and R 4 together form a πng including a -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 -CH 2 -, moiety; R 2 and R 3 are the same or are independently different from one another and represent a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocychc moiety; an oxygen containing heterocychc moiety; a sulfur containing heterocychc moiety; a selenium containing heterocychc moiety; a mixed heterocychc moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, meta or para-substituted benzene; with the proviso that when n=0, R 2 and R 3 are unsubstituted phenyl groups, and X 1 — Y 1 and X 2 — Y 2 are saturated carbon-carbon bonds, Y 1 cannot be CH 2 , CHOH or C=O, and Y 2 cannot be CH 2 , CHOH, or C=0. It is preferred that when R 3 and/or R 4 is a saturated hydrocarbon ring, the πng includes, but is not limited to, cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that when R 3 and/or R 4 is an unsaturated hydrocarbon ring, the πng includes, but is not limited to, benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene, including all possible substitution patterns, geometπc and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that when R 3 and/or R 4 is a nitrogen containing heterocychc moiety, the moiety includes, but is not limited to, azetme, piperdme, piperazme, pyrazme, pyrazole, pyrazolidme, lmidazole lmidazohne, pyπmidine, hexa-hydropynmidme, pyrrole, pyrrohdme, tπazme, 1,2,3-tπazole, 1 ,2,4-tπazole, pyπdine or pyπdazme, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that R 3 and or R 4 is an oxygen containing heterocychc moiety, the moiety includes, but is not limited to, furan, tetrahydrofuran, 2,5-dιhydrofuran, pyran, tetrahydropyran, 1,4-dιoxane, 1,3-dιoxane or 1 ,4-oxathmm, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that when R 3 and/or R 4 is a sulfur containing heterocychc moiety, the moiety includes, but is not limited to, thietane, thiophene, thiophane, 2,5-dιhydrothιophene, 1,3-dιthιolyhum, 1,3-dιthιolane, 1,2-dιthιolyhum, 1 ,2-dιthιolane, thiane, 1,2-dιthιane, 1,3- dithane, 1,4-dιthιane, or thiopyranyhum, including all possible substitution patterns, geometπc and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that when R 3 and or R 4 is a selenium containing heterocychc moiety, the moiety includes, but is not limited to, selenophene, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. It is further preferred that when R 3 and/or R 4 is a mixed heterocychc moiety, the moiety includes, but is not limited to, thiazo dme, thiazole and oxazm, including all possible substitution patterns, geometπc and stereoisomers, racemic, diastereomeπc and enantiomeπc forms thereof. The substituted benzene includes at least one substituent, where the substituent is selected from , but is not limited to, the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ammo, N-methylammo, N,N-dιmethylamιno, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomefhyl, N,N- dimethylammomethyl, carboxamide, N-methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tπfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo and nitroso. It is preferred that when either X 1 — Y 1 or X 2 — Y 2 is a saturated carbon-carbon bond, Y 1 or Y 2 represents CH 2 , CH-OH, CHO-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OS0 2 -C 6 H 5 , CH-OSOz-p-C^CHs, CH-SH, C 6 H 5 -SH, CH-S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N0 2 , CH-CF 3 , CH-NHOH, CH-OCHO, CH-F, CH- Cl, CH-Br, CH-I, CH-NH 2 , CH-NH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N(alkyl) 2 where said alkyl is a lower straight chain or branched alkyl, CH-OCONH 2 , CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH- OCON(alkyl) 2 where said alkyl is a lower straight chain or branched alkyl, CH-N 3 , C=0 or C=S; CH-O-aryl such as a phenyl, ortho-, meta-, or para-substituted phenyl where the substituent is as described above; or a hydrocarbon or hetercychc ring such as pyπdyl, furanyl, naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-tπazole, 1 ,2,4-tπazole, lmidazolme, pyπmidme, pyπdazme or tπazme, including all possible substitution patterns, diastereomeπc and enantiomeπc forms thereof. The lower straight or branched alkyl can be an alkyl group containing one to seven carbon atoms. The preferred alkyl groups are methyl and ethyl. The above 2,6-substιtuted pipeπdmo analogs are preferred their czs-geometncal isomeπc forms, or in their trans geometπc forms, including all possible geometπc, racemic, diasteπomeπc, and enantiomeπc forms thereof The above cιs-2,6-dιsubstιtuted pipeπdmes as well as analogs thereof can be administered in their free base form or as a soluble salt. Whenever it is desired to employ a salt of a cιs-2,6-substιtuted pipeπdme or its analog, it is preferred that a soluble salt be employed Some preferred salts include hydrochloπde, hydrobromide, nitrate, sulfate, phosphate, tartrate, galactarate, fumarate, citrate, maleate, glycolate, malate, ascorbate, lactate, aspartate, glutamate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, sahcylate, propπonate, and succinate salts. The above salt forms may be in some cases hydrates or solvates with alcohols and other solvents. A pharmaceutical composition containing a compound of the invention is also contemplated, which may include a conventional additive, such as a stabilizer, buffer, salt, preservative, filler, flavor enhancer and the like, as known to those skilled in the art Representative buffers include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and the like. A composition of the invention may be administered by inhalation, i.e., mtranasally as an aerosol or nasal formulation; topically, i.e., m the form of an ointment, cream or lotion; orally, i.e., m solid or liquid form (tablet, gel cap, time release capsule, powder, solution, or suspension in aqueous or non aqueous liquid, intravenously as an infusion or injection, i.e., as a solution, suspension or emulsion m a pharmaceutically acceptable earner; transdermally, e.g., via a transdermal patch; rectally as a suppository and the like. Generally, the pharmacologically effective dose of a present compound is m the amount ranging from about 1 x 10 "5 to about 1 mg kg body weight/day. The amount to be administered depends to some extent on the hpophilicity of the specific compound selected, since it is expected that this property of the compound will cause it to partition into fat deposits of the subject. The precise amount to be administered can be determined by the skilled practitioner in view of desired dosages, side effects and medical history of the patient and the like. The cιs-2,6-dιsubstιtuted pipendmo analogs of the present invention exhibit selectivity for either neuronal nicotmic acetylcholme receptors and or the dopamme transporter protein (DAT). The deπvatives that are active towards the nicotmic receptor generally do not interact with the DAT, and those that interact with the DAT show only modest nicotmic receptor activity. (ii) Table 1 Compound Ki (μM) Ki (μM) [ 3 H] -Nicotine Binding [ 3 H]-Dopamme Uptake Assay Assay 1. X' = X 2 = CH 2 0.0043 45 Y 1 = C=0 Y 2 = (S)-CHOH 2. X 1 = X 2 = Y 1 = Y 2 = CH 2 14.3 3.0 3. X' = X 2 = CH 2 0.0041 39 Y 1 = C=0 Y 2 = (S)-CHOS0 2 -C 6 H 4 -p-CH 3 4. X 1 = X 2 = CH 2 11 25 Y 1 = Y 2 = C=0 5. X',Y' = X 2 ,Y 2 = trans CH=CH >100 0.8 6. X 1 = CH 2 0.13 3.0 Y 1 = C=0 X 2 ,Y 2 = trans CH=CH 7. X 1 = X 2 = CH 2 0.93 54 Y 1 = (S)-CHOH Y 2 = (R)-CHOH 8. X' = X 2 = Y 2 = CH 2 0.16 8.9 Y 1 = (RS)-CHOH 9. X' = CH 2 4.2 1.3 Y' = (S)-CHOH X 2 ,Y 2 = trans CH=CH The nine cιs-2,6-dιsubstιtuted pipeπdmo deπvatives listed m Table 1 have the chemical structure of formula (II). They were assayed for nicotmic receptor interaction and inhibition of DAT activity. The cιs-2,6-dιsubstιtuted pipeπdmo analogs of the present invention exhibit selectivity for either neuronal nicotmic acetylcholine receptors and/or the dopamine transporter protein (DAT). The deπvatives that are active towards the nicotmic receptor generally do not interact with the DAT, and those that interact with the DAT show only modest nicotmic receptor activity. The nine compounds in Table 1 were evaluated m the high affinity [ 3 H]nιcotme binding assay and afforded inhibition constants (Ki values) ranging from 0.0043 μM to > 100 μM. Five of these compounds were in the range of 4 - 160 nM. Three of these compounds were in the range of 0.93 - 14 μM. One compound was > 100 μM. The cιs-2,6-dιsubstιtuted pipeπdmo derivatives listed in Table 1 were also assayed for inhibition of DAT activity, i.e., inhibition of [ 3 H]DA uptake into the dopammergic presynaptic terminal. Nine compounds were evaluated and afforded inhibition constants (Ki values) ranging from 0.08 μM to 54 μM. Removal of both functionalities of the lobelme molecule resulted m loss of affinity for the nicotmic receptor and a 100-fold more potent inhibition of the dopamine transporter compared with lobelme. Removal of either the hydroxyl group or the keto group of lobelme resulted in a 50-fold loss of affinity for the nicotmic receptor Interestingly, the ketoalkene analog inhibited DAT 10-fold more potently than lobelme, whereas lobelanidme inhibited DAT equipotently compared to lobelme. Conversion of the hydroxy group of lobelme to a bulky tosyloxy group reduced the affinity of the nicotmic receptor by only 3-fold, but did not alter the interaction with the DA transporter. The hydroxyalkene had a similar potency with the meso- transdiene (the most potent compound) m the DA uptake assay, but had 1000-fold lower affinity for the nicotmic receptor. Also, the completely defunctionahzed lobelme molecule and the hydroxyalkane analog were both less potent than the mesø-transdiene in inhibiting DA uptake into stπatal synaptosomes. This data indicates that appropπate structural modification of the lobelme molecule affords compounds in which the interaction with DAT is enhanced. Furthermore, in one compound, i.e., the røesø-transdiene, the nicotmic receptor interaction has been eliminated and the compound is thus selective for inhibition of DAT. The invention will now be discussed by certain examples that illustrate but do not limit the invention. Example 1 Cf -2.6-dι-/rα« , -styrylpιpendme 1.00 g (2.95 mmol) of lobelamdme was dissolved m 15 ml of 85 % H 3 P0 4 and allowed to stir overnight at 60°C. The reaction mixture was taken up in H 2 0 and made basic with solid K 2 C0 3 (pH~8). The pH was adjusted by the addition of solid NaOH (pH~10). The aqueous solution was extracted three times with 15 ml of EtOAc. The organic layers were combined and dπed over anhydrous MgS0 . The salts were removed via filtration and solvent removed by rotary evaporation affording 0.70 g of crude product. This compound was recrystalhzed from MeOH affording 0.60 g of pure cw-2,6-dι-frα?M-styrylpιpeπdme. Percent yield = 78.6 % Mp = 139-141°C. Η NMR (300 MHz, CDC1 3 ) d: 1.40-1.80 (m, 6H), 2.23 (s, 3H), 2.50-2.64 (t, 2H), 6.04-6.20 (dd, 2H), 6.39-6.50 (d, 2H) and 7.10-7.38 (m, 10H); 13 C NMR (CDC1 3 ) d: 23.75, 33.56, 42.32, 68.36, 126.26, 127.38, 128.61, 130.52, 133.89 and 137.13 ppm. Example 2 Os-2S,6R. 8S-2-r6-(β-pαra-toluenesulfonyloxyphenethyl)- l-methyl-2-pιpeπdyll-acetophenone 1.00 g (2.58 mmol) of lobelme hemisulfate was dissolved in 25 ml of pyndine and was added dropwise to a solution (cooled to 0°C) containing 0.60 g (3.14 mmol) of p-toluenesulfonyl chloride dissolved m 15 ml of pyndine After addition, the reaction was allowed to stir for 2 hours and then poured into 50 ml of ice-cold water and the mixture was stirred for an additional two hours. The aqueous solution was extracted three times with 25 ml of EtOAc. The organic layers were combined and dπed over anhydrous Na 2 S0 4 The salts were removed by filtration and the solvent was removed by rotary evaporation affording 450 mg of a pmk-colored compound. The product was recrystalhzed from acetone yielding 300 mg of the product. Percent yield = 21.6 % mp = 169.1-171.0°C. Η NMR (300 MHz, CDC1 3 ) δ: 1.30-1.98 (m, 6H), 2.20 (s, 3H), 2.63-2.74 (d, 3H), 2.95-3.20 (m, 2H), 3.61-3.78 (d, IH), 3.83-4.12 (m, 2H), 4.50-4.72 (m, IH), 4.80-4.90 (d, IH), 6.90-7.00 (d, 2H), 7.10-7.50 (m, 8H), 7.50-7.60 (d, 2H), 7.80-7.90 (d, 2H) and 9.85 (s, IH); 13 C NMR (CDC1 3 ) δ: 21.16, 22.25, 23.32, 23.55, 27.35, 38.29, 40.18, 40.07, 60.79, 63.69, 71.05, 125.56, 125.76, 127.39, 128.28, 128.44, 128.69, 128.77, 133 67, 133.96, 135.87, 140.03, 141.98, 144.47 and 195.21 ppm. Example 3 Cz5-2S.6R-N-methyl-6-phenacyl-2-/rα»^-styτylpιpeπdme 1.00 g (2.58 mmol) of lobelme hemisulfate was dissolved in 15 ml of 85 % H 3 P0 4 and the solution was allowed to stir for 24 hrs at 50°C . Phosphoric acid was then neutralized with K 2 C0 3 , and a little ice cold H 2 0 was added to dissolve the salts. The aqueous solution was extracted with ethyl acetate (20 ml x 3). The organic layers were combined and dried with anhydrous MgS0 4 . The salts were removed by filtration and the solvent was removed via rotary evaporation, affording 0.80 g of a gummy solid, which contained mainly the trans isomer. Percent yield = 84.6 %. Η NMR (300 MHz, CDC1 3 ) 1.15-1.60 (m, 6H), 2.02 (s, 3H), 2.47-2 71 (m, 3H), 3.16-3.34 (dd, IH), 5.80-6.00 (dd, IH), 6.18-6.28 (d, IH), and 6.90-7.38 (m, 8H) and 7.64-7.80 (d, 2H); !3 C NMR (CDC1 3 ) 23.52, 32.56, 33.17, 40.52, 44.02, 59.62, 68.08, 126.00, 127.15, 127.92, 128.36, 128.44, 130.29, 132.91, 133.91, 136.95, 136.99 and 198.83 ppm. Example 4 ethyll-2-/rαn^-styrylpιpendme In a 250 ml round bottom flask was added 0.80 g of -2S,6R-N-methyl-6-phenacyl-2- frøns-styrylp pendme, and 50 ml of ethanol. Sodium borohydπde was added until all of the starting mateπal was consumed (determined by TLC). The solution was cooled to 0°C and acetone was added in small portions to quench the reaction. The solvents were evaporated to dryness and water was added precipitating 0.75 g of an off-white crystalline solid (1.1) mixture of diastereomers, which was puπfied on silica elutmg with 75:25 (CHC1 3 / EtOH). The yield of the product (a mixture of diastereomers) was 93 4 % Η NMR (300 MHz, CDC1 3 ) δ 1 17-2 06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50-6.20 (m, 4H), 2.70-3.20 (m, 4H), 4 78-4.80 (dd, IH), 5.04-5.14 (dd, IH), 5.96-6.20 (m, 2H), 6 32-6.42 (dd, 2H) and 7 04-7.34 (m, 20H), 13 C NMR (CDCI 3 ) δ: 23.69, 24.15, 26.74, 29.68, 33.26, 39.94, 41.10, 41.41, 62.93, 63.00, 65.62, 68.32, 71.76, 73.90, 125.46, 126.15, 126.19, 126.83, 127.01, 127.37, 128.16, 128.23, 128.50, 130.58, 132.61, 133.85, 136.83, 136.95, 145.32 and 145.45 ppm. Example 5 C;5-2S.6R-N-methyl-6-| " l-(2-hvdroxy-2-phenyl)ethyll-2-ρhenylethylpιpendme 0.50 g (1.55 mmol) of cw-2S,6R-N-methyl-6-phenacyl-2-/ra«5-styrylpιpeπdιne was dissolved 50 ml of ethanol and placed into a Parr hydrogenation apparatus with 0.10 g of 10 % Pd-on-Carbon. After removal of air, hydrogen gas was introduced until a pressure of 40 psig was reached. The reaction was allowed to proceed for 48 hrs. The Pd catalyst was removed through filtration with Celite, and ethanol was removed by rotary evaporation to afford 0.30 g of a yellow oil. The compound was puπfied by silica gel chromatography elutmg with EtOAc to afford 0.25 g of the product. The yield was 50.0 %. Η NMR (300 MHz, CDC1 3 ) δ: 0.70-0.90 (m, 6H), 1.18 (s, 3H), 1.40-1.90 (m, 6H), 2.44-2.56 (m, 2H), 4.56-4.60 (dd, IH) and 7.04-7.30 (m, 10H); 13 C NMR (CDC1 3 ) δ: 25.77, 29.24, 29.38, 29.42, 29.46, 29.68, 31.44, 35.93, 39.07, 74.64, 125.50, 125.85, 127.42, 128.17, 128.35, 128.37, 142.85 and 144.91 ppm. Example 6 High Affinity | "3 H]Nιcotine Binding Assay The ability to displace S(-)[ 3 H]NIC binding from rat stπatal membranes to assess interaction with the α4β2 subtype was determined. The [ 3 H]NIC binding assay was performed according to previously published methods (Romano et al., 1980; Marks et al., 1986, Crooks et al., 1995). Stπata from two rats were dissected, pooled and homogenized with a Tekmar polytron in 10 vol of ice-cold modified Krebs-HEPES buffer (in mM; 20 HEPES, 118 NaCl, 4.8 KC1, 2.5 CaCl 2 , 1.2 MgS0 4 , adjusted to pH to 7.5). The homogenate was incubated at 37°C for 5 minutes to promote hydrolysis of endogenous acetylcholme, and centπfuged at 15,000 g for 20 minutes and the pellet was resuspended m 10 vol of ice-cold distilled water and incubated at 37°C for 5 minutes, followed by centπfugation at 15,000 g for 20 mm. The pellet containing the stπatal membranes was resuspended in 10 vol of fresh ice-cold 10% Krebs-HEPES buffer and incubated at 37°C for 10 mm after which it was centπfuged at 15,000 g for 20 minutes The latter sequence of resuspension, incubation and centπfugation was repeated. The pellet was frozen under fresh Krebs-HEPES buffer and stored at -40°C until assay. Upon assay, the pellet was resuspended in Krebs-HEPES buffer, incubated at 37°C for 5 minutes and centπfuged at 15,000 g for 20 mm The final pellet was resuspended in 3.6 ml ice-cold water which provides for approximately 200 μg protein/100 μl aliquot Competition assays were performed m duplicate in a final volume of 200 μl Krebs-HEPES buffer containing 250 mM Tπs buffer (pH 7.5 at 4°C). Reactions were initiated by addition of 100 μl of membrane suspension to 3 nM [ 3 H]NIC (50 μl) and 1 of at least 9 concentrations of analog (50 μl). After 90 minutes incubation at 4°C, reactions were terminated by dilution of the samples with 3 ml of ice-cold buffer followed immediately by filtration through a Whatman GF/B glass fiber filters (presoaked in 0.5% polyethyleneimine (PEI) using a Brandel Cell Harvester. Filters were rmsed 3x with 3 ml of ice-cold buffer, transferred to scintillation vials and 5 ml scintillation cocktail added. Nonspecific binding was defined as binding in the presence of 10 μM NIC. For competition curves, the IC 50 values were corrected for hgand concentration (Cheng et al., 1973). Example 7 r 3 H1Dopamme (r 3 H]DA) Uptake Assay. Stnatal Svnaptosomal Preparation [ 3 H]DA uptake was performed according to a modification of the previously reported methods (Dwoskin et al., 1999). Stπata were homogenized in 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM sodium bicarbonate, pH 7.4) with 12 passes of a teflon-pestle homogemzer (clearance approximately .003 in). The homogenate was centπfuged at 2,000 g, 4°C for 10 mm. The supernatant was centπfuged at 12,000 g, 4°C for 20 minutes. The resulting pellet was resuspended m 1.5 ml ice-cold assay buffer (in mM; 125 NaCl, 5 KC1, 1.5 KH 2 P0 4 , 1.5 MgS0 4 , 1.25 CaCl 2 , 10 glucose, 0.1 L-ascorbate, 25 HEPES, 0.1 EDTA and 0.1 pargyhne; pH 7.4). The final protein concentration was 400 μg/ml. Assays were performed in duplicate m a total vol of 500 μl. Ahquots (50 μl synaptosomal suspension containing 20 μg of protein) were added to assay tubes containing 350 μl buffer and 50 μl of 1 of 9 concentrations (final concentration, 1 nM - 1 mM) of analog or vehicle. Synaptosomes were premcubated at 34°C for 10 mm before the addition of 50 μl of [ 3 H]DA (30.1 Ci/mmole, final concentration 10 nM) and accumulation proceeded for 10 mm at 34°C. High affinity uptake was defined as the difference between accumulation in the absence and presence of 10 μM GBR 12935. Preliminary studies demonstrated that at 10 minutes [ 3 H]DA uptake is within the linear range of the time-response curve when expenments are performed at 34°C Accumulation was terminated by addition of 3 ml ice-cold assay buffer containing 1 mM pyrocatechol and rapid filtration through a Whatman GF/B glass fiber filter paper (presoaked with buffer containing 1 mM pyrocatecol) using a Brandel Cell Harvester. The filters were washed 3 times with 3 ml of 10 ml ice-cold buffer containing 2 mM pyrocatechol, and then transferred to scintillation vials and radioactivity determined (Packard Model B1600TR scintillation counter, Meπden, CT). Protein concentration was determined using bovme serum albumin as the standard (Bradford, 1976). Competition curves for analog inhibition of [ 3 H]DA uptake were generated. Nonlinear regression analysis was used to fit curves either in the absence or presence of 9 concentrations of analog. IC50 values were corrected for concentration of [ 3 H]DA (Cheng-Prusoff, 1973) to yield true inhibition constants (Ki = IC50/[1 + c/Rm]), where c is the concentration of free [ 3 H]DA and Km is the concentration of analog at which half maximal [ 3 H]DA uptake is achieved. These values (Ki) were converted to pKi before statistical analysis. In the examples listed in the Table, a senes of cιs-2,6-dιsubstιtuted pipeπdines, structurally related to lobelme, were synthesized and tested for activity m the high affinity nicotmic receptor binding assay and the dopamine uptake assay to assess the interaction of these pipeπdmes with these specific proteins on the presynaptic terminal of dopammergic neurons in the CNS. Some of these compounds have greater selectivity for interaction with DAT than for interaction with nicotmic receptors, whereas other compounds interact with both nicotmic receptors and DAT, more similar to lobelme. Other compounds were more selective for the nicotmic receptor than for DAT. These combinations of pharmacological activity are considered to be beneficical for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies. The foregoing is considered as illustrative only of the pπnciples of the invention. Further, since numerous modifications and changes will readily occur to those skilled m the art, it is not desired to limit the invention to the exact construction and operation shown and described, and accordingly, all suitable modifications and equivalence thereof may be resorted to, falling withm the scope of the invention claimed. REFERENCES The pertinent disclosures of the references listed below and as discussed above herein are incorporated herein by reference. Barlow R.B. et al., "Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)cystme and (-)lobelme hydrochloπde and a comparison with (-)nιcotιne and other nicotine-like compounds," Br J Pharmacol, 1989; 98" 799-808. Broussolle E.P. et al., "In vivo binding of 3 H-nιcotme in the mouse bram," Life Sciences, 1989; 44- 1123-1132. Cheng Y.C. et al., "Relationship between the inhibition constant (K,) and the concentration of inhibitor which causes 50 percent inhibition (I 50 ) of an enzymatic reaction," Bwchem. Pharmacol, 1973; 22: 3099-3108. Clarke P.B.S. et al., "Release of [ 3 H]noradrenahne from rat hippocampal synaptosomes by nicotine: mediation by different nicotmic receptor subtypes from stnatal [ 3 H]dopamme release," Br. J. Pharmacol, 1993; 45: 571-576. Crooks P.A. et al., "Inhibition of nicotine-evoked dopamine release by pyndmo-N- substituted nicotine analogues: a new class of nicotmic antagonist," Drug Dev Res., 1995; 36 71-82. Decker M. W. et al., "Effects of lobelme, a nicotmic receptor agonist, on learning and memory," Pharmacol Biochem. Behav. 1993; 45: 571-576. Dwoskm L.P. et al., "S-(-)-Cotmme, the major bram metabolite of nicotine, stimulates nicotmic receptors to evoke [ 3 H]dopamme release from rat stnatal slices in a calcium-dependent manner," J. Pharmacol. Exp. Therap., 1999; 288: 905-911. Hamann S.R. et al., "Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)lobehne m the rat bramstem," Pharmacol Biochem Behav., 1994; 47: 197- 201. Lippiello P.M. et al., "The binding of L-[ 3 H]nιcotine to a single class of high affinity sites in rat bram membrane," Mol Pharmacol, 1986, 29: 448-454. Marks MJ. et al., "Nicotine binding sites in rat and mouse bram: comparison of acetylcholme, nicotine and α-bungarotoxm," Mol Pharmacol, 1986; 30: 427-436. Olm B.R. et al., Drug Facts and Comparisons, JB Lippmcott Co., St. Louis, MO, pp 3087-3095 (1995). Romano C. et al., "Stereospecific nicotmic receptors on rat bram membranes," Science, 1980; 210: 647-650. Teng L.H. et al., "Lobelme and nicotine evoke [ 3 H]-overflow from rat stπatal slices preloaded with [ 3 H]dopamme: differential inhibition of synaptosomal and vesicular [ 3 H]dopamιne uptake," J. Pharmacol. Exp Therap., 1997; 80: 1432-1444. Teng L.H. et al, "Lobelme displaces [ 3 H]dιhydrotetrabenazme binding and releases [ 3 H]dopamme from rat sπatal synaptic vesicles," J Neurochem., 1998; 71: 258-265.

Claims: What is claimed is: 1. A method of treating an individual for dependence on a drug of abuse, withdrawal from a drug of abuse, for an eating disorder, or for a CNS disease or pathology comprising administering to the individual an effective amount of a cιs-2,6-substιtuted pipeπdmo compound or pharmaceutically effective salt thereof compπsmg formula (I): wherein: n is zero or an integer from 1 to 3; X 1 — Y 1 and X 2 — Y 2 are the same or are independently different from one another and represent a saturated carbon-carbon bond, a cz ' s-carbon-carbon double bond, a trans ^carbon- carbon double bond, a carbon-carbon tπple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond; R 1 and R 4 are the same or are independently different from one another and represent hydrogen or a lower straight chain or branched alkyl or R 1 and R 4 together form a ring including a -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 -CH 2 -, -cis-CH=CH, - -CH 2 -CH=CH- or -cw-CH 2 =CH-CH 2 - moiety; R 2 and R 3 are the same or are independently different from one another and represent a saturated or unsaturated hydrocarbon rmg; a nitrogen containing heterocychc moiety; an oxygen containing heterocychc moiety; a sulfur containing heterocychc moiety; a selenium containing heterocychc moiety; a mixed heterocychc moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, meta or para- substituted benzene; with the proviso that when n=0, R 2 and R 3 are unsubstituted phenyl groups, and X 1 — Y 1 and X 2 — Y 2 are saturated carbon-carbon bonds, Y 1 cannot be CH 2 , CHOH or C=0, and Y 2 cannot be CH 2 , CHOH, or C=0. 2. The method of claim 1, wherein said drug of abuse is selected from the group consisting of cocaine, amphetamine, caffeine, nicotine, phencyclidme, opiates, barbiturates, benzodiazepmes, canabinoids, hallucinogens, and alcohol. 3. The method of claim 1, wherein in said treatment of an individual for a CNS disease or pathology, is selected from the group consisting of cognitive disorders, bram trauma, memory loss, psychosis, sleep disorders, obsessive compulsive disorders, panic disorders, myasthema gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntmgton's disease, attention deficit disorder, hyperkmetic syndrome, chronic nervous exhaustion, narcolepsy, motion sickness and depression. 4. The method of claim 1, wherein said admmisteπng of the compounds is performed subcutaneously, intramuscularly, intravenously, transdermally, orally, mtranasally, mtrapulmonary or rectally. 5. The method of claim 1, wherein said admimsteπng of the compound inhibits uptake of dopamine by cells of the central nervous system of the individual. 6. The method of claim 1, wherein said admmistenng of the compound inhibits binding of neurotransmitters or drugs to nicotmic receptors on cells of the central nervous system of the individual. 7. The method of claim 1, wherein the eating disorder includes obesity of the individual. 8 The method of claim 1, wherein the individual's desire for said drug of abuse or food is reduced for at least one day. 9 The method of claim 1 , further comprising behavior modification counseling to the individual. 10. The method of claim 1, wherein said admmistenng of the compound alleviates the symptoms of the aforesaid CNS diseases and pathologies. 11. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane. 12 The method of claim 1, wherein the unsaturated hydrocarbon ring includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene 13. The method of claim 1, wherein the nitrogen containing heterocychc moiety includes azetine, pipendme, piperazme, pyrazme, pyrazole, pyrazolidine, imidazole imidazoline, pynmidme, hexa-hydropyπmidme, pyrrole, pyrrolidme, tπazme, 1,2,3-tnazole, 1,2,4-tπazole, pyπdme or pyπdazine. 14. The method of claim 1, wherein the oxygen containing heterocychc moiety includes furan, tetrahydrofuran, 2,5-dιhydrofuran, pyran, tetrahydropyran, 1,4-dιoxane, 1,3- dioxane or 1,4-oxathmm. 15. The method of claim 1, wherein the unsaturated sulfur containing heterocychc moiety includes thietane, thiophene, thiophane, 2,5-dιhydrothιophene, 1,3-dιthιolyhum, 1,3- dithiolane, 1 ,2-dιthιolyhum, 1,2-dιthιolane, thiane, 1 ,2-dιthιane, 1,3-dithane, 1 ,4-dιthιane, or thiopyranyhum. 16. The method of claim 1, wherein the selenium containing heterocychc moiety is selenophene. 17 The method of claim 1, wherein the mixed heterocychc moiety is thiazohdme, thiazole or oxazm. 18. The method of claim 1, wherein the substituted benzene includes at least one substituent selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl, ammo, N-mefhylammo, N,N-dιmethylammo, carboxylate, mefhylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N- dimethylammomethyl, carboxamide, N-methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tπfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo and nitroso. 19. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane; the unsaturated hydrocarbon πng includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; the nitrogen containing heterocychc moiety includes azetine, piperdme, piperazme, pyrazme, pyrazole, pyrazolidine, imidazole imidazoline, pynmidme, hexa- hydropyπmidme, pyπole, pyrrolidme, tπazme, 1,2,3-tnazole, 1,2,4-tπazole, pyndine or pyndazme; the oxygen containing heterocychc moiety includes furan, tetrahydrofuran, 2,5- dihydrofuran, pyran, tetrahydropyran, 1,4-dιoxane, 1,3-dιoxane or 1 ,4-oxathmιn; the sulfur containing heterocychc moiety includes thietane, thiophene, thiophane, 2,5-dιhydrothιophene, 1,3-dιthιolyhum, 1,3-dιthιolane, 1 ,2-dιthιolyhum, 1,2-dιthιolane, thiane, 1 ,2-dιthιane, 1,3- dithane, 1 ,4-dιthιane, or thiopyranyhum; the selenium containing heterocychc moiety includes selenophene; the mixed heterocychc moiety includes thiazohdme, thiazole or oxazm; and the substituent for the substituted benzene includes at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ammo, N-mefhylammo, N,N-dιmethylammo, carboxylate, mefhylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N-dιmethylammomethyl, carboxamide, N- methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, mehtoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tπfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo, and nitroso. 20. The method of claim 19 wherein when either X 1 — Y 1 or X 2 — Y 2 is a saturated carbon-carbon bond, Y 1 or Y 2 represents CH 2 , CH-OH, CHO-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OS0 2 -C 6 H 5 , CH-OS0 2 -p-C 6 H 4 CH 3 , CH-SH, C 6 H,-SH, CH- S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N0 2 , CH-CF 3 , CH- NHOH, CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I, CH-NH 2 , CH-NH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N(alkyl) 2 alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCONH 2 , CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCON(alkyl) 2 where said alkyl is a lower straight chain or branched alkyl, CH-N 3 , C=0 or C=S; CH-O-phenyl, substituted CH-O- phenyl where the substituent is at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ammo, N-methylammo, N,N-dιmethylamιno, carboxylate, mefhylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N- dimethylammomethyl, carboxamide, N-methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tπfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo, and nitroso; or a hydrocarbon or heterocychc ring comprising pyπdyl, furanyl, naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-tnazole, 1,2,4-tnazole, imidazoline, pynmidme, pyndazme or tπazme 21. The method of claim 1, wherein the pharmaceutical salts are hydrochlonde, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound 22. The method of claim 20, wherein the pharmaceutical salts are hydrochlonde, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound 23. The method of claim 1, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms. 24 The method of claim 23, wherein said alkyl is methyl or ethyl. 25. The method of claim 20, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms. 26. The method of claim 25, wherein said alkyl is methyl or ethyl. 27. A cz5-2,6-substιtuted pipeπdino compound or pharmaceutically effective salt thereof comprising formula (I): wherein: n is zero or an integer from 1 to 3; X 1 — Y 1 and X 2 — Y 2 are the same or are independently different from one another and represent a saturated carbon-carbon bond, a czs-carbon-carbon double bond, a trans-czrbon- carbon double bond, a carbon-carbon tπple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond; R 1 and R 4 are the same or are independently different from one another and represent hydrogen or a lower straight chain or branched alkyl or R 1 and R 4 together form a ring including a -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 -CH 2 -, -cis-CH=CH, -cis-CH 2 -CH=CH- or -cis-CH 2 =CH-CH 2 - moiety; R 2 and R 3 are the same or are independently different from one another and represent a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocychc moiety; an oxygen containing heterocychc moiety; a sulfur containing heterocychc moiety; a selenium containing heterocychc moiety; a mixed heterocychc moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, eta or para- substituted benzene, with the proviso that when n=0, R 2 and R 3 are unsubstituted phenyl groups, and X 1 — Y 1 and X 2 — Y 2 are saturated carbon-carbon bonds, Y 1 cannot be CH 2 , CHOH or C=0, and Y 2 cannot be CH 2 , CHOH, or C=0 28. The compound of claim 27, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane. 29 The compound of claim 27, wherein the unsaturated hydrocarbon πng includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene. 30. The compound of claim 27, wherein the nitrogen containing heterocychc moiety includes azetine, pipendme, piperazme, pyrazme, pyrazole, pyrazolidine, imidazole imidazoline, pynmidme, hexa-hydropyπmidme, pyrrole, pyrrolidme, tπazine, 1,2,3-tnazole, 1,2,4-tπazole, pyndine or pyndazme. 31. The compound of claim 27, wherein the oxygen containing heterocychc moiety includes furan, tetrahydrofuran, 2,5-dιhydrofuran, pyran, tetrahydropyran, 1,4-dιoxane, 1,3- dioxane or 1 ,4-oxathmm. 32. The compound of claim 27, wherein the unsaturated sulfur containing heterocychc moiety includes thietane, thiophene, thiophane, 2,5-dιhydrothιophene, 1,3- dithiolyhum, 1,3-dιthιolane, 1,2-dιthιolyhum, 1 ,2-dιthιolane, thiane, 1 ,2-dιthιane, 1,3-dithane, 1 ,4-dιthιane, or thiopyranyhum. 33. The compound of claim 27, wherein the selenium containing heterocychc moiety is selenophene. 34. The compound of claim 27, wherein the mixed heterocychc moiety is thiazohdine, thiazole or oxaz . 35. The compound of claim 27, wherein the substituted benzene includes at least one substituent selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl, ammo, N-methylamino, N,N-dιmethylammo, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N- dimethylammomethyl, carboxamide, N-methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tπfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo and nitroso. 36. The compound of claim 27, wherein the saturated hydrocarbon πng includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane, the unsaturated hydrocarbon nng includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; the nitrogen containing heterocychc moiety includes azetine, piperdme, piperazme, pyrazme, pyrazole, pyrazolidine, imidazole imidazoline, pynmidme, hexa- hydropyπmidine, pyπole, pyrrolidme, tnazine, 1,2,3-tnazole, 1,2,4-tnazole, pyndine or pyndazme; the oxygen containing heterocychc moiety mcludes furan, tetrahydrofuran, 2,5- dihydrofuran, pyran, tetrahydropyran, 1,4-dιoxane, 1,3-dιoxane or 1 ,4-oxathimn; the sulfur containing heterocychc moiety includes thietane, thiophene, thiophane, 2,5-dιhydrothιophene, 1,3-dιthιolyhum, 1,3-dιthιolane, 1 ,2-dιthιolylιum, 1 ,2-dιthιolane, thiane, 1,2-dιthιane, 1,3- dithane, 1 ,4-dιthιane, or thiopyranyhum; the selenium containing heterocychc moiety mcludes selenophene; the mixed heterocychc moiety includes thiazohdme, thiazole or oxazm; and the substituent for the substituted benzene includes at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ammo, N-methylammo, N,N-dιmethylammo, carboxylate, mefhylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N-dιmethylamιnomefhyl, carboxamide, N- methylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, mehtoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, trifluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo, and nitroso. 37. The compound of claim 36 wherein when either X 1 — Y 1 or X" — Y 2 is a saturated carbon-carbon bond, Y 1 or Y 2 represents CH 2 , CH-OH, CHO-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OS0 2 -C 6 H 5 , CH-OS0 2 -p-C 6 H 4 CH 3 , CH-SH, C 6 H 5 -SH, CH- S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N0 2 , CH-CF 3 , CH- NHOH, CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I, CH-NH 2 , CH-NH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N(alkyl) 2 alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCONH 2 , CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCON(alkyl) 2 where said alkyl is a lower straight chain or branched alkyl, CH-N 3 , C=0 or C=S, CH-O-phenyl, substituted CH-O- phenyl where the substituent is at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ammo, N-mefhylammo, N,N-dιmethylammo, carboxylate, mefhylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, ammomethyl, N-methylammomethyl, N,N- dimethylammomethyl, carboxamide, N-mefhylcarboxamide, N,N-dιmethylcarboxamιde, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, lodo, tnfluoromethyl, vmyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylammo, and nitroso; or a hydrocarbon or hetercychc nng comprising pyπdyl, furanyl, naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-tnazole, 1,2,4-tπazole, imidazoline, pynmidme, pyπdazme or tnazme. 38. The compound of claim 27, wherein the pharmaceutical salts are hydrochlonde, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound 39. The compound of claim 37, wherein the pharmaceutical salts are hydrochlonde, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound 40. The compound of claim 27, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms. 41. The compound of claim 40, wherein said alkyl is methyl or ethyl. 42. The compound of claim 37, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms. 43 The compound of claim 42, wherein said alkyl is methyl or ethyl.

Inventors: CROOKS PETER A, DWOSKIN LINDA P, JONES MARLON D, CROOKS, PETER, A., DWOSKIN, LINDA, P., JONES, MARLON, D.
Applicants: UNIV KENTUCKY RES FOUND, UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Application year: 2000
Main classification: A61K31
IPC codes: A61K31, C07D211